John Dawson CBE joins board of Ergomed
Surrey pharmaceutical services company, Ergomed plc, have named John Dawson CBE as a non executive director.
Mr Dawson, CBE joins Ergomed, who offer specialised services to the pharmaceutical industry, as an independent Non-Executive Director and Chair of the Audit Committee.
Dawson is a highly experienced and respected figure in the healthcare sector. A former Chief Executive Officer of Oxford Biomedica (LSE: OXB), where during his 13-year tenure he successfully manufactured the life-saving Oxford/AstraZeneca COVID-19 vaccine.
Subsequently awarded a CBE for services to UK life science in the 2021 New Year Honours List, in recognition of his work on the delivery of the Oxford Biomedica COVID-19 vaccine, Mr Dawson retired from the firm in January of this year.
Under the chartered accountant's leadership, Oxford Biomedica's success resulted in it entering the FTSE 250 index in 2020.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed, said: "As a highly regarded and well-connected figure, John is an outstanding addition to the Ergomed Board, and his wealth of international experience in the healthcare industry will be invaluable as the Company continues to grow.
"The resounding success of Oxford Biomedica is testament to John's strong leadership and expert knowledge of the life science sector. We look forward to utilising his network and benefiting from his extensive experience of working in the UK public markets."
John Dawson, CBE, said: "Ergomed is fast becoming a leading global pharmaceutical services provider, which has seen exceptional growth over the past few years, and which remains at a very exciting stage in its development.
"I look forward to working closely with the Board and Senior Management Team as we continue to build upon this momentum."
